November 28, 2023 02:19 AM ESTUpdated 11:33 AM
R&D

Up­dat­ed: In­jectable form of ar­genx drug Vyv­gart fails PhI­II study in au­toim­mune platelet dis­ease

Ryan Cross

Senior Science Correspondent

A Dutch biotech com­pa­ny that’s post­ed win af­ter win in clin­i­cal stud­ies of its au­toim­mune dis­ease drug dis­closed its first ma­jor fail­ure of the med­i­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times